Presenting on behalf of a large international team, Martin Heidinger (DBM Hebelstrasse, Basel, Switzerland), showed results from a preplanned analysis of the TAXIS/OPBC-03 phase 3 trial. Axillary lymph node dissection (ALND) is the standard of care for patients with node-positive breast cancer after neoadjuvant chemotherapy or upfront surgery. The use of tailored axillary surgery (TAS) to reduce axillary tumour burden…
[News] 2026 Society of Surgical Oncology Annual Meeting
The Lancet Oncology | | David Collingridge
Topics: breast-cancer, chemotherapy, clinical-trials